On March 12, 2014, Lv, Binhua; Li, Chengwei published a patent.Application of 97859-49-9 The title of the patent was Preparation of substituted oxazolidinone compounds as factor Xα inhibitors. And the patent contained the following:
The present invention relates to substituted oxazolidinone compounds I [wherein R1 = 5-(un)substituted 2-thienyl or 4-(un)substituted Ph; R2 = 3-oxo-4-morpholinyl, 2-oxo-1-piperidinyl, etc.; R3 and R4 = independently H, D, F, Cl, OH, CN, etc.; R5 and R6 = independently H, D, F, Cl, OH, etc.; with proviso], pharmaceutically acceptable salts, crystal forms, hydrates, or solvates thereof as factor Xα inhibitors for treating and/or preventing thromboembolic diseases. For example, II was prepared in a multi-step synthesis. The title compounds showed inhibitory activity with IC50 < 50 nM against human blood-coagulation factor Xα. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Application of 97859-49-9
The Article related to preparation oxazolidinone factor xa inhibitor treatment thromboembolic disease human, Heterocyclic Compounds (More Than One Hetero Atom): Oxazines (Including Morpholine) and other aspects.Application of 97859-49-9
Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem